Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Summary

The purpose of the study is to determine whether the administration of bevacizumab and gemcitabine given by IV infusion can prolong survival, delay tumor growth, and/or shrink tumors in patients with ovarian cancer, primary peritoneal, or fallopian tube cancer.

Timeline

Start

2011-01

Primary completion

2011-09

Completion

2011-09

Outcome

Outcome not reported

Stopped: “PI left Emory”

Drugs

Indications